Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer

This publication has 31 references indexed in Scilit:

• Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer
  Clinical Cancer Research, 2006
• Clinical Efforts to Combine Endocrine Agents with Targeted Therapies against Epidermal Growth Factor Receptor/Human Epidermal Growth Factor Receptor 2 and Mammalian Target of Rapamycin in Breast Cancer
  Clinical Cancer Research, 2006
• The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling
  Endocrine-Related Cancer, 2005
• Serum HER‐2/neu conversion to positive at the time of disease progression in patients with breast carcinoma on hormone therapy
  Cancer, 2005
• Enhanced Estrogen Receptor (ER) α, ERBB2, and MAPK Signal Transduction Pathways Operate during the Adaptation of MCF-7 Cells to Long Term Estrogen Deprivation
  Journal of Biological Chemistry, 2003
• Insulin-like Growth Factor Receptor Levels Are Regulated by Cell Density and by Long Term Estrogen Deprivation in MCF7 Human Breast Cancer Cells
  Published by Elsevier ,2001
• Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α
  Journal of Biological Chemistry, 2001
• Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cells in Vivo
  Endocrinology, 2000
• Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.
  Endocrine-Related Cancer, 1999
• Estrogen Receptor Expression and Function in Long-Term Estrogen-Deprived Human Breast Cancer Cells
  Endocrinology, 1998